Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns

Assessment of measurable residual disease (MRD) upon treatment of acute myeloid leukemia (AML) remains challenging. It is usually addressed by highly sensitive PCR- or sequencing-based screening of specific mutations, or by multiparametric flow cytometry. However, not all patients have suitable muta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2022-01, Vol.36 (1), p.80-89
Hauptverfasser:	Božić, Tanja, Kuo, Chao-Chung, Hapala, Jan, Franzen, Julia, Eipel, Monika, Platzbecker, Uwe, Kirschner, Martin, Beier, Fabian, Jost, Edgar, Thiede, Christian, Wagner, Wolfgang
Format:	Artikel
Sprache:	eng
Schlagworte:	38/22 38/61 45/23 631/208/69 631/67/1990/283/1897 692/699/67/68/2486 Acute myeloid leukemia Algorithms Biomarkers, Tumor - genetics Bisulfite Cancer Research Chromosomes CpG islands Critical Care Medicine Crosstalk Deep learning Deoxyribonucleic acid DNA DNA Methylation Epigenetics Flow cytometry Gene Expression Regulation, Leukemic Hematology Hematopoiesis Heterogeneity Homology Humans Intensive Internal Medicine Learning algorithms Leukemia Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Machine learning Medicine Medicine & Public Health Mutation Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Neoplasm, Residual - genetics Neoplasm, Residual - pathology Oncology Prognosis Standardization Surface markers Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!